Versant Venture Capital VI, L.P. 13D/13G Filings for Aligos Therapeutics, Inc. (ALGS)

Versant Venture Capital VI, L.P. 13D and 13G filings for Aligos Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2024-02-08
5:44 pm
Unchanged
2023-11-0213DALIGOS THERAPEUTICS INC
ALGS
Versant Venture Capital VI, L.P.58,317
1.900%
0
(Unchanged)
Filing
2021-06-21
4:44 pm
Sale
2021-06-1113DALIGOS THERAPEUTICS INC
ALGS
Versant Venture Capital VI, L.P.58,317
3.800%
-19,440decrease
(-25.00%)
Filing